We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session

Urology
6018
Poster (Digital)
Clinical
Toxicity and early findings in a post-prostatectomy ablative radiation therapy multicentric trial
Denis Panizza, Italy
PO-1452
SBRT for prostate cancer with or without Elective Nodal Irradiation
Juan Canales, Chile
PO-1454
Impact of pelvic irradiation on fiducial tracking prior to SBRT for high-risk prostate cancer
Jonathan Lischalk, USA
PO-1455
PSMA-guided management of oligorecurrent post-prostatectomy patients: focus on SBRT
Giuseppe Carlo Iorio, Italy
PO-1456
Concordance of number and site of metastases with PET/CT vs conventional imaging in prostate cancer
HODA ABDEL-ATY, United Kingdom
PO-1457
Stereotactic focused radiotherapy for low-risk prostate cancer: results of a Phase-II trial
Paul Nguyen, Belgium
PO-1458
Stereotactic salvage radiotherapy for prostate red relapse, early analysis from a prospective trial
Giulio Francolini, Italy
PO-1459
MR Delta Radiomics during Radiotherapy to Prostate Cancer: Does Dose per Fraction Matter?
Martin Swinton, United Kingdom
PO-1460
Omission of pelvic RT in elderly patients with prostate cancer. Institutional experience
Gustavo Ferraris, Argentina
PO-1461
Patient-reported outcome measures after salvage radiotherapy for prostate cancer
Christine Vestergaard Madsen, Denmark
PO-1462
1.5T MR-guided SBRT for Oligometastatic Prostate Cancer: Toxicity and Clinical Outcomes
JING YUAN, Hong Kong (SAR) China
PO-1463
5-year survival and toxicity results of SIB radiotherapy in (very) high-risk prostate cancer
Stephane Supiot, France
PO-1465
PFS Following SBRT for Visceral Oligometastatic Prostate Cancer: A Multicenter Retrospective Study
Maximilien Rogé, France
PO-1466
Influence of PSMA-PET on treatment of prostate cancer patients with biochemical recurrence
Ingerid Skjei Knudtsen, Norway
PO-1468
dose escalation in hypofractionated radiotherapy in prostate cancer : early and late toxicity
Kevin QUINTIN, France
PO-1469
Treatment outcomes of non-metastatic small cell carcinoma of the urinary bladder
Hyun Ju Kim, Korea Republic of
PO-1470
PSMA-PET-based Definitive Radiotherapy for Patients with Prostate Cancer – Outcome and Feasibility
Marco M.E. Vogel, Germany
PO-1471
Hypofractionated post-prostatectomy radiotherapy in 16 fractions: a single institution outcome
Pavol Dubinsky, Slovakia
PO-1472
PSMA PET imaging of non-acinar histological variants of prostate cancer
Comron Hassanzadeh, USA
PO-1473
Adjuvant radiotherapy of prostate cancer: a comprehensive analysis of toxicity predictors
Letizia Cavallini, Italy
PO-1474
Ultra-hypofractionated SABR in High risk prostate cancer: preliminary results of a phase II trial
Angel Montero, Spain
PO-1475
Extreme hypofractionated SBRT for elderly prostate cancer patients: results of a phase II trial
Alba Fiorentino , Italy
PO-1476
10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer
VICTOR DUQUE-SANTANA, Spain
PO-1477
Value of a systematic cardiac workup by a cardiologist for prostate cancer patients treated with ADT
Maximilien Rogé, France
PO-1478
Management of androgen deprivation therapy (ADT) by French radiation oncologists, TALISMAN study
Gilles Crehange, France
PO-1479
Time to testosterone recovery following long-course LHRH agonists and prostate cancer outcomes
Katharine Webb, United Kingdom
PO-1480
Moderately hypofractionated proton therapy with implantable spacer in patients with prostate cancer
Vicky Kaviraj Soborun, Germany
PO-1482
Persistent urinary symptoms and long-term quality of life after prostate cancer radiotherapy
Sofia Spampinato, The Netherlands
PO-1483
SBRT for prostate cancer: analysis of CBCT guided radiotherapy and on-line correction
Jose Antonio Solis Campos, Chile
PO-1484
Local recurrence of prostate cancer after curative RT: the role of salvage SBRT re-irradiation
Riccardo Carlo Sigillo, Italy
PO-1488
MRI sensitivity in detecting macroscopic local recurrences in prostate cancer:an observational study
Letizia Cavallini, Italy
PO-1489
Prostate cancer nodal relapse: impact of CRPC and previous RT on salvage ENRT+PET guided SIB outcome
Nadia Di Muzio, Italy
PO-1490
Profiling PCa patients with BCR in the era of early imaging detection: an AIRO-URO group study
Giulia Marvaso, Italy
PO-1491
Ultra Hypo RT in elderly PCa patients with aggressive disease: still a space for curative approach?
Giulia Marvaso, Italy
PO-1492
Health-related quality of life in extreme hypofractionation for localized prostate cancer
Diego Bongiovanni, Italy
PO-1493
Process mining in PCa Salvage RT patients care path: an AIRO-URO group preliminary analysis
Federico Mastroleo, Italy
PO-1494
Sparing Neurovascular bundle with hyaluronic acid rectal spacer: a prospective study.
Sara Simoes, Portugal
PO-1495
Acute toxicity rates and predictors in extreme hypofractionation for localized prostate cancer
Giuseppe Carlo Iorio, Italy
PO-1496
MRgSBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis
Andrea D'Aviero, Italy
PO-1497
Stereotactic re-RT for local recurrence of PCa after primary surgery and RT: a retrospective study.
Mattia Zaffaroni, Italy
PO-1498
Extracranial stereotactic radiotherapy in low and favourable intermediate risk prostate cancer
Victoria Navarro Aznar, Spain
PO-1499
Safety and feasibility of SBRT for elderly and frail patient with locally advanced bladder cancer
Giulia Marvaso, Italy
PO-1500
HERMES: Are we delivering?
Rosalyne Westley, United Kingdom
PO-1501
Prostate cancer in younger patients: Does it make a difference in oncological outcomes?
Nejla Fourati, Tunisia
PO-1502
Quality of life in oligometastatic prostate cancer patients treated with SBRT using EORTC form
Jing Ma, Germany
PO-1504
Ultrahypofractionated Proton RT in Prostate Cancer: a single-center two-year experience
Nikita Kataev, Russian Federation
PO-1505
FIRST BRC AFTER RP: choline/PSMA-PET or mpMRI guided-SBRT on DETECTABLE PROSTATE BED RECURRENCE
Maria Giulia Vincini, Italy
PO-1506
Urinary toxicity after prostate cancer stereotactic reirradiation : frequency and predictors
Renaud de Crevoisier, France
PO-1508
Predictors of Patient-Reported decline in Social activity 2-years after WPRT for prostate cancer
Cesare Cozzarini, Italy
PO-1509
PSMA-PET and PCa: an exploratory analysis beyond the numerical definition of oligometastatic state
Maria Giulia Vincini, Italy
PO-1510
Ultrahypofractionated prostate radiotherapy: toxicty and patient reported outcomes
jacqueline ogg, United Kingdom
PO-1511
radical chemoradiotherapy to the bladder: review of practice at the Northern Centre for Cancer Care
Anthony Waton, United Kingdom
PO-1512
The Roach formula and elective nodal irradiation for prostate cancer in the era of PSMA PET imaging
Femi Walkins, Ireland
PO-1513
SBRT for clinically localized prostate cancer: a propensity scores analysis between two RT schedules
Marco Trovo, Italy
PO-1514
Intrafractional prostate movements and toxicity in a randomized trial with small-margin radiotherapy
Johan Staby Olsén, Sweden
PO-1515
Quality of Life After Radical Treatment for Bladder Cancer – lived experience of patients & carers.
Sally Appleyard, United Kingdom
PO-1516
Stereotactic body radiotherapy in bone oligometastatic prostate cancer: a retrospective study
Silvia Scoccianti, Italy
PO-1520
Ga68-PSMA PETCT response-adapted metastasis directed RT in hormone-sensitive prostate cancer
Prachi Mehta, India
PO-1521
The validity of treatment plan using contours propagated by DIR on MR-Linac in prostate cancer.
Makoto Saito, Japan
PO-1522
Comparison of machine learning methods to predict urinary incontinence in localized prostate cancer
Hajar Hasannejadasl, The Netherlands
PO-1523
SBRT boost is a viable alternative to HDR brachytherapy boost for prostate cancer patients
Daša Grabec, Slovenia
PO-1524
Evaluation of novel dose-volume constraints in patients treated with EBRT for local prostate cancer
Niall O'Sullivan, Ireland
PO-1525
Hypo-fractionated radiotherapy in elderly bladder cancer patients unfit for trimodal therapy.
Fatjona Kraja, Albania
PO-1526
REPAIR-GETUG P16: stereotactic reirradiation with metformin for relapse in irradiated prostate bed
Stephane Supiot, France
PO-1527
SBRT to lymph node in oligometastatic prostate cancer: monoistitutional preliminary report
Paolo Bonome, Italy
PO-1528
Association between age-related parameters and acute toxicity in prostate cancer radiotherapy
Katarzyna Paal, Austria
PO-1529
Long-term outcomes of proton beam therapy for elderly patients with prostate cancer
Takashi Iizumi, Japan
PO-1532
Applicability of SBRT for early prostate cancer and correlation with CTV variation during treatment
Antonio Angrisani, Italy
PO-1533
STAMPEDE2 trial: A site survey of current patterns of care, access to imaging and treatment
HODA ABDEL-ATY, United Kingdom
PO-1534
Using weekly digital patient-reported outcomes to evaluate toxicity for patients at the MR-linac
Pia Krause Møller, Denmark
PO-1536
What factors may influence late urinary toxicities after radiation therapy of prostate cancers?
Nejla Fourati, Tunisia
PO-1537
Quality of life in prostate cancer patients treated with definitive hypofractionated radiotherapy
Jing Ma, Germany
PO-1539
Stereotactic MRguided adaptive radiotherapy in prostate cancer:Real life experience of 180 patients
prantik das, United Kingdom
PO-1541
Seminal vesicle displacement with Hydrogel spacer insertion on prostate radiotherapy
Kenji Makita, Japan
PO-1542
Assessing the Toxicity After Moderately Hypofractionated Whole Pelvis Radiotherapy
Matthias Moll, Austria
PO-1543
Outcomes comparison using PSA cut-off values of 0.1 at 6 months in high-risk prostate cancer
Abdenour Nabid, Canada
PO-1544
Systematic registration of CTCAE and PROMs for patients having standard RT for prostate cancer
Martin Berg, Denmark
PO-1546